Sun Piaoyang

CEO, Jiangsu Hengrui Medicine

Real-Time Net Worth

$13.1B

As of December 2025

Age

Source

Pharmaceuticals

Industry

healthcare

Citizenship

Biography

Sun Piaoyang is a prominent Chinese billionaire and pharmaceutical executive, currently the chairman of Jiangsu Hengrui Medicine. Born in 1958, he earned degrees from China Pharmaceutical University and Nanjing University. Sun transformed Jiangsu Hengrui Medicine into a leading pharmaceutical company specializing in anti-infection and cancer medications. His career spans over three decades, marked by strategic leadership and a focus on research and development. His net worth is estimated at $13.1 billion, and he is married to Zhong Huijuan, who is the chairwoman of Hansoh Pharmaceutical. Sun's leadership has been pivotal in Hengrui's growth, making it a key player in the healthcare industry in China.

Wealth Over Time

In-Depth Profile

Early Life

Sun Piaoyang was born in Lianyungang, China, in 1958. He showed exceptional academic abilities from a young age. He earned a Bachelor's degree from China Pharmaceutical University and a doctorate from Nanjing University.

Rise to Success

Sun Piaoyang took over Jiangsu Hengrui Medicine in 1990. At the time, the company was a relatively small regional pharmaceutical manufacturer. Under his direction, Jiangsu Hengrui Medicine became one of China's largest producers of anti-infection and anti-cancer medicines. He focused on research and development in the areas of oncology and cardiovascular treatments. Jiangsu Hengrui Medicine was listed on the Shanghai Stock Exchange in 2000. The company later completed a listing in Hong Kong in 2025, raising $1.3 billion.

Key Business Strategies

Sun Piaoyang transformed Jiangsu Hengrui Medicine by focusing on innovation and research. He increased investment in research and development, setting the company apart from other pharmaceutical manufacturers in China.

Philanthropy

Information on Sun Piaoyang's specific philanthropic activities and amounts is not readily available in the search results. However, his leadership reflects a commitment to societal well-being and healthcare advancement.

Career Milestones

1990

Took over Jiangsu Hengrui Medicine

Sun Piaoyang became the head of the company and transformed it into a leading pharmaceutical company.

2000

Jiangsu Hengrui Medicine went public

Jiangsu Hengrui Medicine was listed on the Shanghai Stock Exchange.

2025

Hong Kong listing

Sun led the firm to complete a Hong Kong listing in 2025, raising $1.3 billion.

Philanthropy & Social Impact

Healthcare

Healthcare Initiatives

Undisclosed

Sun is dedicated to societal well-being and healthcare advancement.